Gilead Terminates Cicletanine Trial; All Eyes Remain on Quad

Gilead Sciences Inc., of Foster City, Calif., has terminated a Phase II trial of cicletanine for pulmonary arterial hypertension (PAH) due to a failure of the trial to meet its primary endpoint of improvement in exercise capacity.

Gilead acquired cicletanine from Navitas Assets LLC in 2008 for a $10.9 million up-front payment and milestones. The drug is approved in some European countries for hypertension.